Articles from ONI

ONI's new integrated fluidics system, Aplo Flow, automates the most complex multiplexed imaging workflows, helping researchers unlock reproducible 15 nm-resolution experiments at scale.

ONI (Oxford Nanoimaging), a life science tools company focused on developing super-resolution microscopy, announced today the launch of the Aplo Scope, a single molecule super-resolution microscope that enables scientists to observe and measure molecular interactions within cells and tissues with unparalleled precision.

ONI, the biotechnology company broadly enabling the ability to observe single molecules in living cells with its desktop Nanoimager microscopy platform, today announced that Paul Scagnetti has been appointed as the company's new CEO, effective February 27, 2023. Along with this leadership change, ONI will begin to implement a new strategy to accelerate commercial growth and expand its impact in research and discovery. Paul succeeds founding CEO, Bo Jing, who will remain with ONI as a key contributor in product development to help inspire ONI’s next innovations.

ONI, a single-molecule imaging platform biotech, today announced a research collaboration with the University of Pennsylvania, one of the true pioneers of CAR-T (chimeric antigen t-cell) research and clinical trials. The collaboration aims to enhance the understanding of CAR-T therapies using super-resolution microscopy, identifying predictive biomarkers and characteristics related to CAR-T treatment efficacy and safety, with the goal of improving patient outcomes. ONI’s flagship product, the Nanoimager, will allow these researchers to visualize living cells and track how single molecules interact. With a resolution down to 20 nanometres (a 10-fold improvement vs traditional microscopy), the presence and distribution of these biomarkers on CAR-T and tumor cells from patient samples can also be quantified.

ONI, a biotechnology company democratizing the ability to observe single molecules in living cells with its desktop Nanoimager microscopy platform, today announced the closing of a $75 million Series B financing. The round was led by ARCH Venture Partners and Casdin Capital, with participation from Section 32, ARTIS Ventures, Vertical Venture Partners, Axon Ventures and private investors, including Paul Conley. Existing investors, including Oxford Science Enterprises, also participated in the round.

ONI, a rapidly growing company redefining the boundaries of microscopy with its Nanoimager platform that enables imaging of individual molecules in living cells, today announced the early release of its new, single imaging, extracellular vesicle (EV) comsumable kit, during the virtual 10th Annual Meeting of the International Society for Extracellular Vesicles (ISEV2021) taking place May 18-21, 2021.

ONI, a rapidly growing company redefining the boundaries of microscopy with its Nanoimager platform that enables imaging of individual molecules in living cells, today announced that Tyler Ralston, PhD, has joined the company as Chief Technology Officer (CTO). In this role, Dr. Ralston will provide leadership, strategic vision and oversee the research and development for advancing ONI's technology. ONI has developed and started commercializing transformative single molecule microscopy solutions that have significant impact on scientific discoveries in the emerging area of extracellular vesicles research as well as applied markets, such as immuno-oncology and virus detection.